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Abstract
Inefficient intracellular protein trafficking is a critical issue in the pathogenesis of a variety of diseases and in recombinant
protein production. Here we investigated the trafficking of factor VIII (FVIII), which is affected in the coagulation disorder
hemophilia A. We hypothesized that chemical chaperones may be useful to enhance folding and processing of FVIII in
recombinant protein production, and as a therapeutic approach in patients with impaired FVIII secretion. A tagged B-
domain-deleted version of human FVIII was expressed in cultured Chinese Hamster Ovary cells to mimic the industrial
production of this important protein. Of several chemical chaperones tested, the addition of betaine resulted in increased
secretion of FVIII, by increasing solubility of intracellular FVIII aggregates and improving transport from endoplasmic
reticulum to Golgi. Similar results were obtained in experiments monitoring recombinant full-length FVIII. Oral betaine
administration also increased FVIII and factor IX (FIX) plasma levels in FVIII or FIX knockout mice following gene transfer.
Moreover, in vitro and in vivo applications of betaine were also able to rescue a trafficking-defective FVIII mutant
(FVIIIQ305P). We conclude that chemical chaperones such as betaine might represent a useful treatment concept for
hemophilia and other diseases caused by deficient intracellular protein trafficking.
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Introduction
Low molecular weight compounds termed ‘‘chemical chaper-
ones’’ (CC) can inhibit aggregation and restore trafficking of
intracellularly misfolded proteins. They stabilize native protein
conformations non-specifically and support escape from endoplas-
mic quality control systems [1,2]. CC are currently under
investigation for treatment of certain proteopathies or so called
conformational disorders [3] such as nephrogenic diabetes
insipidus caused by vasopressin V2 receptor mutants [4] or
diabetes mellitus [5]. The CC sodium-4-phenylbutyrate has
already been approved for phase II clinical trials for the treatment
of cystic fibrosis [6,7]. Betaine is under clinical evaluation for
treatment of primary hyperoxaluria [8].
In hemophilia A, protein substitution with recombinant factor
VIII (rFVIII) concentrate is the treatment of choice. It is estimated
that due to high treatment costs, only 30% of affected individuals
worldwide receive any kind of hemophilia therapy [9]. This fact
highlights the necessity for alternative strategies that can improve
the clinical outcome, reduce factor consumption or decrease
production costs. rFVIII cannot be produced in bacterial systems,
because diverse post-translational modifications and complex
formation are necessary for FVIII functionality [10]. Therefore,
industrial production relies on mammalian cells that provide the
essential enzyme repertoire for mature FVIII-heterodimer synthe-
sis. In such cell factories, secretion of recombinant FVIII remains
inefficient, as a result of several limiting factors. These include low
FVIII mRNA-levels (with heterologous expression levels 2 to 3
orders of magnitude below other recombinant proteins [11,12],
inefficient translation of the large FVIII transcript, and poor
transport rates between the endoplasmic reticulum (ER) and the
Golgi apparatus [12,13]. We have previously observed in confocal
microscopy studies, that the bulk of the translated protein is
retained in ER or ERGIC [13]. The ER has a limited capacity to
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partially folded polypeptides. Within the ER of cells, a quality
control system employing molecular chaperones has the task of
preventing transit of such mis-folded proteins from ER to Golgi
[14]. Swaroop et al. have shown that FVIII interacts with the
chaperones immunoglobulin-binding protein (BiP/GRP78) [15],
calnexin, and calreticulin [16], which results in formation of non-
disulfide-bonded high molecular weight aggregates in the ER.
These misfolded FVIII proteins are subsequently designated for
proteasomal and lysosomal degradation [17]. Nevertheless, a
number of different modifications in recombinant FVIII have
helped increase secretion efficiency. After the large B domain
structure was identified as dispensable for FVIII coagulant activity,
B-domain deletion (BDD) has been used as a strategy for improved
intracellular trafficking of rhFVIII. Despite 20-fold higher mRNA
expression levels, the additional yield of secreted B-domain deleted
FVIII was only increased to between 30 and 50% [18].
Reintroduction of 226 amino acids of the B-domain with 6 N-
linked oligosaccharides, and mutation of the BiP binding site at
Phe309, further enhanced FVIII secretion [15,19], confirming the
critical role of the glycosylation status and chaperone interaction
for FVIII folding and trafficking. Similar limitations have been
observed in FVIII gene transfer approaches [20,21].
We hypothesized that CC would increase the efficacy of mature
rFVIII protein production and might benefit the treatment of
hemophilia A caused by secretion-defective FVIII mutations.
Testing various CC on their effect on FVIII secretion, the amino
acid derivative betaine emerged as the strongest modifier of
secretion levels. Since betaine is not cytotoxic, frequently used as
food supplement, and already used in patients suffering from
hyperhomocysteinemia, we further investigated oral administra-
tion of betaine in murine models of hemophilia A and B. In this
context trafficking-defective FVIII were investigated. Missense
mutations in all domains of FVIII can impair folding of FVIII and
disturb its intracellular transport, which results in reduced FVIII
plasma levels. Hemophilia A patients with missense mutations
present with clinical phenotypes ranging from mild to severe [22].
Often they are characterized by low circulating antigen levels
while many mutated proteins retain functionality. Here, rescue of
trafficking-defective FVIII mutants was documented in vitro as well
as in vivo. Prophylactic treatment studies have demonstrated that
factor levels above one percent are sufficient to prevent most of the
long term implications of hemophilia, such as disabling arthrop-
athy and muscular atrophy [23]. Thus even a minimal increment
of FVIII or FIX levels by alternative treatment strategies, such as
proposed here, could provide relevant clinical benefit.
Materials and Methods
Ethics Statement
All animal studies were carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. All
animal procedures were approved by the animal protection and
use authority Regierungspraesidium Darmstadt (Approval number
F27/08).
Animal Experiments
FVIII-deficient mice with an exon 16 disruption on a C56Bl/6
background [24] were ordered by Charles River GmbH (Sulzfeld,
Germany). FIX-deficient mice on a C57Bl/6 background were
kindly provided by Katherine High [25]. Minicircle DNA was
injected hydrodynamically via the tail vein as previously described
[26] and 2% (w/v) anhydrous betaine was administered solubi-
lized in drinking water ad libitum for defined time periods:
Drinking water was replenished at least every 48 h. FVIII
knockout mice received hydrodynamic injections of 20 mgo f
Minicircle-DNA expressing hFVIII-BDD or FVIII-BDDQ305P.
Using a cross-over design, 24 hours following gene transfer, mice
were randomly assigned to the control or the betaine-treated
group for 3 days, then plasma samples were retroorbitally collected
and treatment was switched between the groups for another 3 day-
interval. In FIX knockout mice 17.6 mg (50 pmol) of pSL-hFIX
vector were administered. Treatment occurred for 3 and then
further 14 days until sampling, followed by a one-week interrup-
tion with subsequent crossover of groups for another 3 plus 14
days.
Cell Lines and Culture Conditions
Chinese Hamster Ovary (ACC 110) and HepG2 (ACC 180) cell
lines were maintained in Dulbecco’s modified Eagle medium
supplemented with 2 mM L-glutamine, 100 IU/ml penicillin,
100 mg/ml streptomycin, and between 10 and 20% heat-inacti-
vated fetal bovine serum (FBS) (Invitrogen, Belgium).
Chemical Chaperones
Betaine (B14290), butylated hydroxyanisole (B1253), curcumin
(C7727) sorbitol, thapsigargin (T9033), TMAO and taurine were
from Sigma-Aldrich (Taufkirchen, Germany). Sodium 4-phenyl-
butyrate was from Axxora (Lo ¨rrach, Germany), ectoine from
Biomol (Hamburg, Germany).
Lentiviral Constructs and Production of Lentiviral
Supernatants
cDNAs of human FVIII full length (FL) protein, FVIII B-
domain deleted (BDD) protein [27], FVIII-BDD-eGFP [28] or a
mutant FVIII-BDD protein were introduced in the lentiviral
transfer vector pMF363 (Fig. 1). Vector production, concentration,
and titration was performed as previously described [28]. Cells
were kept for at least two weeks post transduction to ensure stable
FVIII-expression prior to the start of the experiment.
Generation of FVIII Mutants
Mutations were introduced by site directed mutagenesis (Quik-
ChangeH II XL Site-Directed Mutagenesis Kit, Agilent Technol-
ogies, Waldbronn, Germany) in lentiviral transfervector pMF363
[29] coding for FVIII-BDD. The resulting vectors, pMF363
FVIII-BDDQ305P and pMF363 FVIII-BDDW2313A, were used
for transduction of HepG2 cells at a multiplicity of infection (MOI)
of 10.
Non Viral Vector Constructs
The human FIX mini-gene was used flanked by the hepatic
locus control region 1, the human alpha-1 anti-trypsin promoter
and a bovine growth hormone polyadenylation signal (HCR/
hAAT-FIX) as described previously [26]. The expression cassette
was introduced into a plasmid vector containing the pSL1180
backbone resulting in the pSL-FIX vector (Fig. 1).
Human FVIII-BDD or FVIII-BDDQ305P cDNA was excised
from pMF363-vectors and cloned 39 of a chimeric intron (from
pCI-neo vector, Promega, WI) in a minicircle producer plasmid
p2WC31 kindly provided by Mark Kay [30] (Fig. 1). Minicircles
were produced as described [26], followed by a restriction digest
(Plasmid-Safe DNase, Epicentre, WI) to eliminate contamination
with residual plasmid backbone sequences.
Chemical Chaperones for Hemophilia A Therapy
PLOS ONE | www.plosone.org 2 September 2012 | Volume 7 | Issue 9 | e44505Chemical Chaperone Treatment of Heterologous Cell
Lines
As expression systems we used CHO or HepG2 cells stably
transduced with self-inactivating lentiviral vectors (MOI 10)
carrying human FVIII-FL or –BDD, a mutant or enhanced
Green Fluorescent Protein (eGFP)-tagged FVIII-BDD protein.
Experiments were performed in 96 well plates with 1 to 2*10e4
cells per well. After cell adherence overnight media was
supplemented with CC at different concentrations. After 72 h
incubation with CC, levels of active FVIII were determined in the
supernatants. To reveal toxic effects of CC, Hoechst 33342
staining (Thermo Fisher Scientific, Germany) was used to count
adherent cells in 96 well plates. Experiments were performed in
duplicates.
FVIII and FIX Assays
FVIII activity in cell supernatant or mouse plasma was
measured by the Coamatic chromogenic assay using normal
human reference plasma for calibration according to the
manufacturer (both Haemochrom Diagnostica, Germany). Hu-
man FVIII antigen in mouse plasma or cell lysates was quantified
in comparison to recombinant human FVIII-BDD (ReFacto,
Pfizer GmbH, Germany) using a sandwich ELISA (F8C-EIA
FVIII:C, Affinity Biologicals, ON, Canada). 1 IU of ReFacto was
defined as 100 ng FVIII Protein/ml. Human FIX concentrations
were determined using an ELISA in which a monoclonal antibody
to human FIX, clone HIX-1 (Sigma, St Louis, MO), was used as
capture antibody. Peroxidase-conjugated polyclonal goat anti–
human FIX (Affinity Biologicals, Hamilton, ON) was used as
detection antibody. Mouse FIX levels were determined by a
modified one-stage factor assay, by incubating 25 ml human FIX–
deficient plasma with 25 ml automated activated partial thrombo-
plastin time (aPTT) reagent (Dade Behring, Marburg, Germany)
and a total of 25 ml of a test sample (diluted in human FIX-
deficient plasma).
Triton-soluble and Insoluble Fractionation of Intracellular
FVIII
Intracellular FVIII was fractioned into Triton X-100-soluble
and insoluble fractions as previously described [31] with minor
modifications of the lysis buffers. CHO cells transduced with eGFP
tagged hFVIII-BDD were treated with 50 or 100 mM betaine or
control. After 72 h cells were washed twice in ice-cold PBS and
lysed in ice-cold lysis buffer containing protease inhibitors [PBS/
0.5% Triton X-100]. Cells were sedimented at 16,0006g for
30 min at 4uC. Supernatants were transferred into new tubes and
saved as the detergent-soluble fraction. Pellets were washed twice
with lysis buffer, were subsequently solubilized with SDS buffer
(1% SDS instead of TX-100) and centrifuged for further 30 min.
The supernatant was saved as Triton X-100 insoluble fraction.
hFVIII distribution was analyzed by Western Blotting and indirect
FVIII-ELISA (Affinity Biologicals, ON, Canada).
Western Blot
Cell lysate fractions were centrifuged at 16,0006g for 20 min.
Equal volumes were separated by SDS-PAGE (4–20% Gradient
Gels, Thermo Fisher Scientific, Germany), transferred to nitro-
cellulose membranes and probed with anti-GFP rabbit serum
(Roche Diagnostics GmbH, Mannheim Germany) or anti hFVIII
Light Chain goat antibody (F-15). Internal control was done using
anti-hGAPDH goat antibody (V-18, both SCBT Inc, Santa Cruz,
CA).
FACS Analysis
CHO cells expressing hFVIII-BDD-eGFP were incubated with
50 or 100 mM betaine for 48 or 72 h. Pellets were twice washed
with PBS and resuspended in 16 CellFix (Becton Dickinson,
Heidelberg, Germany). Intensity of hFVIII-BDD-eGFP expression
(X mean GFP) in control versus betaine- or BHA-treated cells was
determined in FACScan using CellQuest software (Becton
Dickinson, Germany).
Figure 1. DNA constructs used in the in vitro or in vivo studies. Expression cassettes including domain structure of hFVIII-transgene or exon-
structure of hFIX, promoter and enhancer elements. hFVIII-BDDeGFP has been previously described by Heinz et al. [25]. (A) In vitro lentiviral constructs
were used for transduction of cell lines. (B) In vivo a hFIX-Minigene encoding plasmid was hydrodynamically injected in Hem B mice, whereas hFVIII-
BDD or hFVIII-BDDQ305P expressing minicircles were produced for Hem A mouse studies. Asterisks indicate locations of point mutations.
doi:10.1371/journal.pone.0044505.g001
Chemical Chaperones for Hemophilia A Therapy
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CHO cells expressing eGFP-tagged hFVIII-BDD proteins were
seeded on coverslips in six-well plates and incubated for 72 h with
or without betaine 100 mM. The eGFP signal of eGFP-FVIII
fusion proteins could be directly detected by fluorescence
microscopy. For immunofluorescent labeling of Golgi matrix
protein 130 (GM130) cells were fixed with 3.5% paraformalde-
hyde, permeabilized with 0.1% Triton X-100 and blocked with
3% human serum albumin in PBS. Detection was performed by
incubation with rabbit anti-GM130 antibody (H-65) and Alexa
543-
labeled anti-rabbit IgG secondary antibody (both antibodies,
SCBT Inc., Santa Cruz, CA). Hoechst 33342 (Invitrogen) was
used to stain the cell nucleus. Coverslips were mounted on to slides
with Mowiol 4–88 (Carl Roth GmbH, Karlsruhe, Germany) and
stored at 4uC. Images of immunostained cells were recorded on a
fluorescence Axiovert 100 microscope (Zeiss AG, Jena, Germany).
Statistical Analysis
Two-tailed paired Student’s t-tests or repeated measures
ANOVA with Dunnetts Multiple comparison post test (GraphPad
InStat Software 3.06, La Jolla, CA) were used for comparisons
between CC-treated and untreated cells or mice. The Wilcoxon
Signed Rank Test was employed for non-parametrical analysis.
Results
CC Supplementation Increases Secretion of Recombinant
FL-, BDD- and eGFP Tagged BDD- FVIII
Initially, we tested members of different compound classes of
CC for their effect on hFVIII-BDD expression in CHO cells:
Polyols (sorbitol) [32], sugars (trehalose) [33], methylamines
(betaine) [6] and trimethylamine N-oxide (TMAO) [4], free amino
acids such as taurine [5] or amino acid derivatives (ectoine) [34]
(Fig. 1A). Beside the former listed osmolytes, we tested the
hydrophobic compound sodium-4-phenylbutyrate (PBA), which
has already been tested as a chemical chaperone in a cystic fibrosis
clinical trial [7]. Concentrations were selected based on reported
data from conformational disorders, but were additionally
pretested for cytotoxicity on CHO cells by determining cell count
after 72 h of treatment using Hoechst 33342 nuclear stain (Sigma-
Aldrich, Germany). Resulting test concentrations were: Betaine
(100; 50; 25 mM); ectoine, trehalose, sorbitol and taurine (150;
100; 50 mM); trimethylamine N-oxide (TMAO; 50; 25; 12,5 mM)
and sodium 4-phenylbutyrate (4-PBA; 2; 0,4 mM). The screening
for secretion-supporting CC identified two promising candidates,
betaine and ectoine. The other CC showed no effect on CHO cells
(Fig. 2A).
In addition, another class of substances, the endoplasmic
ATPase inhibitors, was also examined. These substances have
been shown to successfully rescue trafficking of mutant CFTR in
vitro [35] or to cause improved maturation of vasopressin V2
receptor mutants involved in nephrogenic diabetes insipidus [4].
We could show that addition of betaine, ectoine or curcumin all
increased the secretion rate of eGFP-tagged hFVIII–BDD proteins
in CHO cells (Fig. 2B). Thapsigargin alone showed no effect; a
concentration of 10 mM was toxic to the cells. Addition of
100 mM betaine proved to be most effective, increasing the yield
of secreted active hFVIII-BDD 1.9-fold. In contrast, the control
substance butylated hydroxyanisol (BHA) had no effect on secreted
FVIII yield (Fig. 2B). BHA is an antioxidant which was previously
reported to improve cell integrity and survival when applied
previously to induction of FVIII expression in a CHO cell line. It
increased FVIII secretion by reduction of intracellular FVIII-
accumulation and decreased oxidative stress evoked by induction.
However, upon application to already FVIII producing cells no
reduction of the apoptosis rate was detected [36]. As 100 mM
betaine slightly inhibited cell growth in this experiment we
supplemented betaine treatment at a concentration of 50 mM in
combination with ectoine, thapsigargin or curcumin to achieve
higher effects. CC combinations increased FVIII secretion
synergistically, but did not exceed the effect of 100 mM betaine
supplementation alone (Fig. 2B). Kinetics of 50 and 100 mM
betaine treatment showed that the secretion rate increased
significantly after 48 h hours of incubation (Fig. 2C). Betaine
addition was also the most effective treatment in cells expressing
FVIII-FL and led to up to 2.6-fold higher levels of secretion at
50 mM betaine concentration. 10 mM thapsigargin showed a
modest effect on FVIII secretion, while curcumin showed no effect
(Fig. 2D).
Increased FVIII Levels are not Attributed to Improved
Stability of FVIII in Cell Culture Supernatant or Plasma
To exclude the possibility that the cause of increased FVIII
levels was a result of improved stability of extracellular FVIII, the
supernatant of CHO FVIII-BDDeGFP cells was incubated with
representative concentrations of betaine, ectoine, thapsigargin,
and curcumin. FVIII activity was determined at different time
points. Only ectoine, which is known as a protein stabilizer,
showed a mild stabilizing effect on FVIII. There were no
differences in FVIII-concentration after 6, 24 or 72 h following
incubation with all other substances tested compared to non-
treated controls (Fig. 3A). Incubation in normal human plasma
(Haemochrom Diagnostica) did also not affect FVIII half life
(Fig. 3B).
Betaine Improves Intracellular FVIII Solubility and
Corrects Processing of eGFP-tagged FVIII
FACS analysis of betaine treated eGFP-FVIII expressing cells
revealed a shift in eGFP fluorescence intensity compared to
control cells. Incubation with either 50 mM or 100 mM betaine
increased expression of hFVIII-BDDeGFP after 48 (Fig. 4A) and
72 h (Fig. 4B), whereas butylated hydroxyanisole (BHA) treatment
had no effect. We hypothesized that the betaine-induced higher
secretion rate might correspond to higher intracellular concentra-
tions, due in turn to increased intracellular FVIII solubility and
higher levels of correctly folded proteins. To test this hypothesis,
the amount of FVIII antigen in the detergent-soluble fraction (TX-
100) and the detergent-insoluble fraction (SDS) of cell lysates was
compared in ELISA and Western blot analysis. In CHO cells
expressing an eGFP-tagged FVIII protein, 100 mM betaine
treatment induced redistribution of intracellular FVIII antigen
into the TX-100 soluble fraction (Fig. 4C). Less FVIII was found
in the detergent-insoluble fraction, which is supposed to contain
protein aggregates possibly targeted for degradation. During
processing, FVIII is transported from the ER to the Golgi, where
the FVIII single-chain is cut into a light and a heavy chain to form
a secretion-competent heterodimer. To examine the effect of
betaine on the maturity grade of FVIII we determined the relative
amount of single chain versus light chain in both fractions by
Western Blotting (Fig. 4D). These experiments revealed that in the
detergent-soluble fraction the lower band of the light chain doublet
(D) became stronger after betaine treatment, whereas the single
chain band was weaker. In the SDS insoluble fraction only the
single chain was detectable, but this also became weaker after
betaine treatment.
Chemical Chaperones for Hemophilia A Therapy
PLOS ONE | www.plosone.org 4 September 2012 | Volume 7 | Issue 9 | e44505Figure 2. CC improve secretion of FVIII-BDD, FVIII-BDD-eGFP and FVIII-FL in vitro. Heterologous CHO cells were incubated with CC at
different concentrations. FVIII activity was determined in cell supernatants after 72 h by chromogenic assay. (A) Effect of the following CC on human
(h)FVIII-BDD secretion: Betaine (100; 50; 25 mM), ectoine (150; 100; 50 mM), trehalose (150; 100; 50 mM), sorbitol (150; 100; 50 mM), taurine (150; 100;
50 mM), trimethylamine N-oxide (TMAO;50; 25; 12,5 mM) and sodium 4-phenylbutyrate (4-PBA; 2; 0,4 mM). Number of experiments, n=2. (B) Effect
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Immunofluorescence analysis revealed an altered intracellular
distribution of FVIII proteins (Fig. 5A). In untreated cells the
endoplasmic reticulum was distributed throughout the whole
cytoplasm and the hFVIII-BDD-eGFP protein was relatively
evenly distributed. In contrast, in betaine-treated cells the
perinuclear localization of hFVIII-BDD eGFP was clearly more
visible. Furthermore, in some cells, some FVIII accumulations
could be seen to co-localize with the cis-Golgi marker GM130.
Live cell imaging by spinning disk confocal microscopy of hFVIII-
BDD eGFP also revealed that in the presence of betaine, there was
a decrease in the number of static FVIII-positive structures,
accompanied by an increase in the number of fast-moving
punctuate elements (Fig. 5B and C).
Betaine Increases hFVIII Plasma Levels in Gene-corrected
FVIII Knockout Mice
To test the effect of betaine on FVIII secretion in vivo,w e
injected FVIII knockout mice with FVIII-BDD minicircle vectors.
To better compare the course of hFVIII plasma levels under
betaine and control conditions in the same mice, we decided for a
crossover study design. We divided the mice into two groups,
receiving either 2% betaine supplemented drinking water ad
libitum or regular tap water as control. After 3 days, blood samples
were retroorbitally collected and the treatment was switched
between groups for further 3 days, ending with a second sampling.
For analysis the parameters hFVIII:C, hFVIII:Ag, and mFIX:C in
the murine plasma were measured. Following non-viral gene
transfer, the highest expression levels are usually observed in the
first 3 days of treatment [26] and then decrease until reaching
stable expression levels between 4 and 8 weeks post treatment.
Since human FVIII can induce an immune response in FVIII
knockout mice, all experiments were performed within one week
following gene transfer, to exclude the possibility of confounding
effects of antibodies on FVIII expression levels. Despite the
expected drop in FVIII over the time of the experiment, attributed
to the gene transfer procedure, betaine supplementation stabilized
and slightly increased the hFVIII antigen and hFVIII:C levels in
group I mice (Fig. 6A and D). Group II showed significantly lower
hFVIII levels after discontinuation of betaine treatment (Fig. 6B
and E). Taken together, in 16 out of 20 mice, the FVIII:Ag levels
were between 1.5 and 3.8-fold higher during the period of drug
of betaine, ectoine, and the endoplasmatic ATPase inhibitors curcumin and thapsigargin on FVIII-.BDD-eGFP secretion. Butylated hydroxyanisole
(BHA) is added as treatment control. n=3. The mean FVIII secretion level 6 SD of untreated hFVIII-BDD-eGFP expressing cells was 19612 IU per 10e6
cells per 72 h. (C) FVIII-BDD-eGFP secretion into cell supernatants over time at different betaine concentrations. n=3. (D) Influence of betaine,
ectoine, curcumin and thapsigargin on FVIII-FL secretion 72 hours following drug supplementation. n=3. All values are presented as means 6 SEM.
ANOVA test * P,.05; ** P,.001.
doi:10.1371/journal.pone.0044505.g002
Figure 3. Influence of CC on FVIII stability in supernatant or plasma. CHO cells were incubated with supernatant from CHO cells expressing
FVIII-BDD. Then representative CC concentrations were supplemented for 6, 24 h and 72 h (A) at 37uC. (B) Human normal plasma from Haemochrom
Diagnostica (Germany) was incubated with CC for 72 h at 37uC. FVIII activity was determined using a two-stage chromogenic assay. Values are
presented as means 6 SEM, the number of independent experiments was n=4.
doi:10.1371/journal.pone.0044505.g003
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fold (Fig. 6F).
Betaine Improves FIX Plasma Levels in Gene-corrected
FIX Knockout Mice
A similar experiment was performed in FIX knockout mice
following human FIX gene transfer. Since long-term expression of
human FIX following minicircle gene transfer is not associated
with an immune response, we started betaine supplementation
when mice reached stable expression levels 8 weeks following FIX
gene transfer. Additionally, using ELISA, we confirmed the
absence of anti-FIX antibodies (data not shown). Betaine-
supplemented, or regular drinking water, was provided for 17
days to equally-sized groups of mice. Betaine addition was then
paused for one week, before re-starting each group on the
alternative treatment. Human FIX ELISA revealed a 1.4-fold
increase after 3 days with a further increase after 2 additional
weeks of betaine treatment (Fig. 6G). After discontinuing betaine
treatment, FIX levels dropped significantly (Fig. 6H). Overall, FIX
levels increased on average 1.5-fold after 17 days of betaine
treatment (Fig. 6I).
Betaine Supplementation Rescues Secretion-defective
FVIII Mutations in vitro and in vivo
Since chemical chaperone treatment improved secretion of
FVIII-BDD in vitro and in vivo, we asked whether betaine could also
increase the secretion of secretion-defective FVIII proteins.
Representatively, we chose two missense mutations that have
been identified in hemophilia A patients and which are known to
cause protein misfolding and ER retention. Amino acid substitu-
tion Q305P [37] is located in the A1 domain of FVIII, whereas
W2313A [38] lies towards the C-terminus of the C2 domain
(Fig. 7A and B). Mutant FVIII-BDD proteins were expressed in
HepG2 cells. Cells were incubated with betaine or ectoine for 72 h
and FVIII activity was determined in a two stage assay. The levels
of both mutant FVIII proteins in the supernatant increased up to
2-fold with increasing betaine concentrations (Fig. 7A and B).
Supplementation of ectoine also resulted in 1.5-fold higher levels.
In this assay, 100 mM betaine inhibited cell proliferation.
Therefore we combined 50 mM betaine and 100 mM ectoine
treatment. Both had a slightly synergistic effect in HepG2 FVIII-
BDDQ305P-expressing cells (2.5-fold) as well as in HepG2 FVIII-
BDDW2313A-producing cells, with minimal cell growth inhibi-
tion (Fig. 7C). The TX-100/SDS solubility assay of HepG2 FVIII-
BDDQ305P showed that more than 95% of the mutant hFVIII-
antigen in the lysates was found in the TX-100 insoluble fraction
(data not shown). Betaine induced a redistribution of intracellular
FVIII antigen into the TX-100 soluble fraction similar to the effect
observed in hFVIII-BDD secreting CHO cells, but to a lesser
extent (Fig. 7D). 100 mM betaine treatment reduced the amount
of hFVIII-antigen trapped in the detergent-insoluble fraction
about 60 percent.
In vivo we examined betaine treatment in FVIII knockout mice
expressing mutant human FVIII-BDDQ305P. The experimental
design was identical to the human FVIII studies in mice described
above. The starting plasma levels of FVIII-BDDQ305P were
Figure 4. Betaine increases solubility of intracellular FVIII. CHO cells expressing eGFP-tagged FVIII-BDD protein were incubated with and
without betaine. (A,B) Flow cytometry analysis was used to determine the eGFP-signal in untreated cells versus cells treated with betaine or control
substance BHA. The mean eGFP intensity (X mean GFP) in the range M1 was used as distinctive parameter. (A) representative histogram after 48 h of
treatment and (B) values after 72 h presented as means 6 SEM of 3 independent experiments. ANOVA **P,.001. (C,D) After 72 h incubation cells
were successively lysed in PBS/0.5% Triton X-100 and PBS/1% SDS. (C) FVIII antigen was determined in both fractions by indirect ELISA. (D) Triton X-
100-soluble and insoluble fractions were separated on SDS-polyacrylamid gradient gels, and hFVIII light chains (lc), eGFP in hFVIII-single chain (sc) and
GAPDH were detected by Western blot. D indicates lower band of hFVIII lc doublet.
doi:10.1371/journal.pone.0044505.g004
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(Fig. 6). In group I the mice which switched from pure tap water to
betaine supplementation for 3 days showed an increase in FVIII-
BDDQ305P activity and antigen levels. In the mice treated with
betaine in the first part of the study we could only detect FVIII
activity in a single mouse after switching to pure tap water for 3
days. Therefore only animals which received betaine in the end of
the experiment retained residual FVIII activity 8 days post
injection (Fig. 7H and I), which corresponded to higher FVIII
antigen levels (Fig. 7E and F).
Betaine has no Influence on Endogenous Mouse
Coagulation Factors VIII or IX
To examine betaine influence on endogenous plasma proteins
in the mouse models, we additionally monitored mouse coagula-
tion factors VIII or IX in all collected samples from all treatment
groups. Betaine treatment did not change murine FVIII or FIX
activities (Fig. 7K and L).
Discussion
Here we show that supplementation with CC can improve
FVIII secretion both in cell culture and in vivo. In initial screening
of CC candidates, the substance betaine showed the highest
potency, in that it doubled the amount of secreted FVIII. Secreted
FVIII was fully functional, which indicates no major limitation in
other posttranslational processes required by the secreted protein.
Other substances known to improve protein secretion either had
no effect, or only a very mild effect, on secretion of FVIII. One
possible explanation for this finding is the significant cellular
toxicity observed with CC concentrations needed to enhance
FVIII trafficking for these substances. On the other hand,
experiments exploiting other CCs are derived from secretion
studies of mis-folded mutant proteins. Here, we tested a system in
which FVIII is already trapped in the ER as a result of an overload
of the cell’s folding capacity, in turn due to high levels of
recombinant protein over-expression. Betaine therefore appears to
be an attractive option to overcome current limitations in
pharmaceutical FVIII-production. In fact, a previous report
described that betaine preserves cell viability at hyperosmolar
conditions and therefore adds to increased productivity of
thrombopoietin in CHO cells under these conditions [39]. In
addition, we observed that ectoine, thapsigargin and curcumin
were able to further increase FVIII secretion when applied in
combination with betaine. While ectoine is an osmolyte similar to
betaine, the ER-ATPase inhibitors thapsigargin and curcumin
reduce calcium levels in ER, which in turn alters interactions with
calcium-dependent chaperones such calnexin and calreticulin
[35], or affects the structure of MCFD2. Both of these scenarios
might therefore produce additive effects.
In previous studies we observed that BDD FVIII concentrations
in the ER are higher, and FVIII transport is more likely to occur
by bulk flow, compared to FVIII FL [13,28]. By contrast, the
transport of the FL protein is primarily receptor mediated using
LMAN1 and MCFD2 [40]. Different optimal betaine concentra-
tions in FVIII-FL and –BDD expressing cell lines might therefore
result in differences in protein trafficking. Supportingly as the
administration of thapsigargin only improved FVIII-FL secretion,
it seems to be more susceptive for alteration of the calcium level in
the ER than FVIII-BDD. The B-domain contains most of the N-
glycans which had to pass the quality control by the calnexin/
calreticulin cycle. Both endoplasmic lectins are also known for
prolonged binding of apparently misfolded glycoproteins. Possibly
thapsigargin could influence these calcium-sensitive chaperone
interactions with the B-domain and release FVIII-FL. An
alternative hypothesis to consider could be differential betaine
sensitivity of cell clones.
Betaine is proposed to stabilize proteins according to the
‘‘preferential exclusion‘‘ model [3,41]. The model hypothesizes
that compatible solutes are excluded from the protein hydrate-
sheath. The osmolytes are repelled form the peptide backbone due
to osmophobic interactions, whereby water molecules are pushed
to the protein surface, resulting in the protein adopting a more
compact conformation [42]. This process reduces inter-protein
interactions by surface-exposed hydrophobic patches, leading to
aggregate formation and could probably alter chaperone accessi-
bility to proteins. In our study, betaine increases the proportion of
correctly folded and processed FVIII in cell lysates. The total
amount of detergent-soluble intracellular FVIII was higher,
whereas the amount of FVIII in the insoluble fraction decreased.
The improved solubility possibly points to an augmentation of
transport-competent FVIII in the ER and a reduction of protein
aggregation. Western blot analysis revealed that betaine also
improved the maturity of FVIII, as more single-chain was cut into
light and heavy chains, a process which requires transport from
the ER to the Golgi. Likewise Santana et al. [8] observed that
betaine showed best results amongst various other CC in reversing
the solubility and restoring the enzymatic activity of the mutant
alanin:glyoxylate-aminotransferase protein (AGXT*LTM). Mis-
folded AGXT*LTM tends to build inactive aggregates in primary
hyperoxaluria type 1 disease. The enzyme deficiency results in
toxic oxalate accumulation in the kidney of homozygous patients.
The authors could demonstrate that betaine induced an increase
of soluble AGXT*LTM in COS-7 cell lysates accompanied by a
reduction of insoluble protein. However the total protein amount
remained unaffected. A similar effect was also shown for another
methylamine, TMAO, in the correction of myocilin-causing
glaucoma [43]. In transfected cells TMAO improved the secretion
of the aggregation-prone D384N mutant through increased
solubility. Additionally, TMAO induced redistribution of the
mutant protein from an ER-enriched to Golgi-enriched fraction in
a density gradient system.
Our immunofluorescence staining suggested that the major
portion of the translated FVIII protein is retained in the ER and
does not reach the Golgi apparatus. These results are in
accordance with our previous work in COS-7 cell lines [13]. If
Figure 5. Betaine improves correct FVIII folding and ER-to-Golgi-Transport. CHO cells expressing eGFP-tagged FVIII-BDD protein were
incubated with and without 100 mM betaine for 72 h. (A) Representative fluorescence microscopy analysis of intracellular FVIII distribution (original
magnification x60). Yellow dots show co-localisation of FVIII (green) with golgi marker GM130 (red). Nuclear staining was done with Hoechst 33342
(blue). Two representative regions of colocalisation are magnified. (B and C) For life imaging cells were seeded on m-slides VI (ibidi GmbH, Germany)
prior to CC incubation. Cell analysis was provided in PBS imaging medium at 37uC by the Advanced Light Microscopy Facility of EMBL (Heidelberg,
Germany) using PerkinElmer Improvision Ultraview Spinning disk confocal microscope combined with Hamamatsu CCD camera (original
magnification x63, numerical aperture 1.4). Video sequences of 120 timepoints, one second each, were taken and analysed with Volocity Version 5.0.3
Build 4 (Improvision Ltd.). (B) Representative snapshots of Betaine and control conditions are shown. Arrows indicate all relatively stationary elements
which were observed in the section, whereas arrowheads indicate only selected mobile FVIII elements, which were highly mobile. (C) Number of
stationary and mobile (.2 mM distance) FVIII-eGFP elements were counted. The mean 6 SD in 15 cells of three movies per condition is shown.
doi:10.1371/journal.pone.0044505.g005
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carriers, mediated by LMAN1/MCFD2-receptors [39,44], prior
to these carriers budding from the ER. These vesicles are
transported to the ERGIC and further on to the Golgi apparatus
[45]. We observed in this study that betaine treatment partially
changes the distribution of FVIII throughout the cell towards an
increased perinuclear staining with punctate FVIII structures co-
localizing with the cis-Golgi marker GM130. GM130 itself is
known to shuttle between the ERGIC and Golgi [46], therefore
one possibility is that the punctate structures of co-localization
could be FVIII-vesicles in transit between the ERGIC and cis-
Golgi. Live imaging analysis supported these findings, as betaine
treatment led to a reduction in the number of FVIII-positive
stationary elements, presumably representing accumulations of
FVIII in ER exit sites or ER-retained FVIII aggregates, with the
concomitant increase in active transport of FVIII.
Figure 6. Betaine feeding improves hFVIII and hFIX secretion in vivo. (A–F) 24 hours post minicircle FVIII-BDD gene transfer the FVIII
knockout mice received water without (group I) or with 2% betaine supplementation in the drinking water (group II, each n=10). After 3 days plasma
samples were collected and each group was monitored for human FVIII antigen (A and B) and related activity levels (D and E) and group treatment
was switched. After another 3 days, plasma levels were tested again. (C and F) represent the calculated overall effect of betaine on FVIII antigen levels
(C) or FVIII activity (D). square symbols indicate samples of the first measuring point, triangles the second one. (G–I) After reaching stable FIX
expression levels following minicircle FIX gene transfer, FIX knockout mice were fed 2% Betaine-supplemented drinking water ad libitum in a
crossover-study of two groups. After 3 and 17 days of treatment, retroorbitally collected plasma samples were monitored for human FIX antigen
levels (G and H). (I) shows the overall change in FIX expression from both groups after 17 days of administration. All values are represented as mean
6 SEM. Same symbols indicate samples of the same mouse at different time points; clear: tap water treatment (control), filled: betaine administration.
Student’s t-test ((G) ANOVA). *P,.05, **P,.005, ***P,.0005.
doi:10.1371/journal.pone.0044505.g006
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explore whether betaine treatment could also increase protein
secretion in vivo. Betaine is a natural methyl group donor in
homocysteine- and methionine-metabolism. The physiological
source of betaine is food (sugar beets, wheat germ, shrimps,
spinach, etc.) [47], or it is generated by oxidizing choline [48]. It
has approval as a dietary supplement in the USA and is commonly
used for commercial feeding. Furthermore, betaine is easily
administered by oral application and is already routinely used in
patients suffering from hyperhomocysteinemia [48]. Since 2001
betaine has been classified as orphan drug for treatment of
homocystinuria by the EMA. Additional to its function as a methyl
donor, betaine is also being evaluated for its function as a CC in a
phase II study in patients with primary hyperoxaluria type 1
(ClinicalTrials.gov Identifier NCT00283387). The disease is
caused by a point mutation, which leads to a secretion defect of
the liver enzyme alanine-glyoxylate aminotransferase. Betaine has
also been tested in pre-clinical settings in cystic fibrosis [6]. Several
mutations leading to a trafficking defect are also known for FVIII
[37,38]. Although these described mutations are rare, 78% (132
out of 170 with documented antigen levels) of missense mutations
listed in the hemophilia A database (Dr. Geoffrey Kemball-Cook,
The Haemophilia A Mutation, Structure, Test and Resource Site,
http://hadb.org.uk, accessed August 18, 2011) have reduced
antigen levels of below 50%, possibly as a consequence of impaired
protein secretion. For this reason, a treatment strategy to improve
protein trafficking could potentially benefit a wider patient
population. Whether the improved processing and secretion of
mutant FVIII protein might increase the risk for inhibitor
formation has not been investigated at this point. In patients with
missense mutations protein secretion is impaired due to intracel-
lular retention of the mutant FVIII, but there is still residual
protein in circulation [49]. Therefore CC-rescued protein would
not be foreign for the immune system. In theory, neo-antigens
could occur due to release of protein that otherwise would never
have reached the circulation. Although we cannot provide data
addressing this concern, we believe that this risk is negligible since
the effect of CC is relatively mild and aims on supporting correct
protein folding rather than release of not correctly processed
FVIII. Here, over-expression in single cells as observed in gene
therapy might carry an even higher risk.
In this study we investigated two representative mutations, one
located in the A1 domain (Q305P) and the other in the C2 domain
(W2313A) of FVIII. Q305P lies within the binding site for
immunoglobulin-binding-protein BiP (T291-F309) and disrupts
the interaction with this chaperone [15,37]. hFVIII-BDDW2313A
is rapidly degraded intracellularly but has 90–100% of the specific
activity of wild-type FVIII-BDD [38]. For both mutations, betaine
supplementation increased secretion of functional protein in cell
culture. Q305P was further evaluated in FVIII deficient mice. For
these experiments, human mutant coagulation factors were
expressed in FVIII deficient mice using non-viral gene transfer.
Addition of betaine to the drinking water resulted in higher
FVIIIQ305P levels, but when betaine treatment was discontinued
FVIII activity returned to baseline.
Similarly, betaine treatment also increased FVIII levels in mice
expressing the human FVIII-BDD without missense mutation. In
contrast, murine FVIII levels remained unchanged. We hypoth-
esized that endogenous murine coagulation factors would be less
affected by betaine treatment. Physiological expression might be
more closely regulated and impaired folding as a result of ER
capacity overload seems unlikely compared to hFVIII over-
expression in limited numbers of liver cells in the gene transfer
setting. To explore this difference, we used a similar gene transfer
approach with the human coagulation FIX for non-viral gene
transfer. Betaine increased recombinant FIX levels but did not
influence endogenous murine FVIII. Although FIX is less affected
by limitations of the ER to Golgi trafficking system, heterologous
overexpression could also lead to impaired folding and processing
of FIX in the ER.
Similar to FVIII, FIX mutations with impaired intracellular
protein processing have also been described [50]. The same is true
for mutations affecting von Willebrand factor [51] and combined
FV/FVIII deficiencies, where an LMAN1/MCFD2 defect causes
FVIII retention in the ER [44]. All of these might therefore be
targets for CC-improved protein secretion.
Acknowledgments
The authors thank Valder Arruda and Katherine High at the Children’s
Hospital of Philadelphia providing mice and FIX constructs, and Halvard
Bo ¨nig, German Red Cross Blood Donor Service, for critical comments and
review of the manuscript.
Author Contributions
Conceived and designed the experiments: SR JS ES TT JCS RP.
Performed the experiments: SR JS PM DA CU PQL. Analyzed the data:
SR JS ES TT JCS RP. Wrote the paper: SR JS.
References
1. Engin F, Hotamisligil GS (2010) Restoring endoplasmic reticulum function by
chemical chaperones: an emerging therapeutic approach for metabolic diseases.
Diabetes Obes Metab 12 Suppl 2: 108–115.
2. Rajan RS, Tsumoto K, Tokunaga M, Tokunaga H, Kita Y (2011) Chemical and
pharmacological chaperones: application for recombinant protein production
and protein folding diseases. Curr Med Chem 18: 1–15.
3. Leandro P, Gomes CM (2008) Protein misfolding in conformational disorders:
rescue of folding defects and chemical chaperoning. Mini Rev Med Chem 8:
901–911.
4. Tamarappoo BK, Verkman AS (1998) Defective aquaporin-2 trafficking in
nephrogenic diabetes insipidus and correction by chemical chaperones. J Clin
Invest 101: 2257–2267.
72 h post betaine treatment. (A and B) show the supplementation of single CC and (C) betaine-ectoine combined treatment. (D) Post CC incubation
HepG2 hFVIII-BDDQ305P cells were successively lysed in PBS/0.5% Triton X-100 and PBS/1% SDS. hFVIII antigen was determined in both fractions by
indirect ELISA. (E–J) hFVIII-BDDQ305P injected Hem A mice were treated with 2% betaine ad libitum per os in a crossover-study of two groups (each
n=10). After 3 days of treatment hFVIII antigen and activity was measured and treatment was switched between mouse groups. 3 days later, plasma
levels were tested again. (E and F) show hFVIII antigen levels, (H and I) the related hFVIII activity levels in plasma of group I or II. (G and J) represent
the calculated overall effect of betaine on FVIII antigen levels (G) or FVIII activity (J). square symbols indicate samples of the first measuring point,
triangles the second one; clear: tap water-administration (control), filled: 2% betaine administration. (K and L) Endogenous murine FIX levels in all
injected FVIII knockout mice (K) and murine FVIII levels of all used FIX knockout mice (L) with and without betaine in the drinking water. Normal
mouse levels were set to 100%. Values are presented as means 6 SEM. (A–D) ANOVA; (E–H; K–L) Student’s t-test; (I–J) Wilcoxon signed rank
test;*P,.05, **P,.005, ***P,.0005.
doi:10.1371/journal.pone.0044505.g007
Chemical Chaperones for Hemophilia A Therapy
PLOS ONE | www.plosone.org 12 September 2012 | Volume 7 | Issue 9 | e445055. Ozcan U, Yilmaz E, Ozcan L, Furuhashi M, Vaillancourt E, et al. (2006)
Chemical chaperones reduce ER stress and restore glucose homeostasis in a
mouse model of type 2 diabetes. Science 313: 1137–1140.
6. Zhang XM, Wang XT, Yue H, Leung SW, Thibodeau PH, et al. (2003)
Organic solutes rescue the functional defect in delta F508 cystic fibrosis
transmembrane conductance regulator. J Biol Chem 278: 51232–51242.
7. Rubenstein RC, Zeitlin PL (1998) A pilot clinical trial of oral sodium 4-
phenylbutyrate (Buphenyl) in deltaF508-homozygous cystic fibrosis patients:
partial restoration of nasal epithelial CFTR function. Am J Respir Crit Care
Med 157: 484–490.
8. Santana A, Salido E, Torres A, Shapiro LJ (2003) Primary hyperoxaluria type 1
in the Canary Islands: a conformational disease due to I244T mutation in the
P11L-containing alanine:glyoxylate aminotransferase. Proc Natl Acad Sci USA
100: 7277–7282.
9. O’Mahony B, Black C (2005) Expanding hemophilia care in developing
countries. Semin Thromb Hemost 31: 561–568.
10. Lenting PJ, van Mourik JA, Mertens K (1998) The life cycle of coagulation factor
VIII in view of its structure and function. Blood 92: 3983–3996.
11. Chuah MK, Vandendriessche T, Morgan RA (1995) Development and analysis
of retroviral vectors expressing human factor VIII as a potential gene therapy for
hemophilia A. Hum Gene Ther 6: 1363–1377.
12. Soukharev S, Hammond D, Ananyeva NM, Anderson JA, Hauser CA, et al.
(2002) Expression of factor VIII in recombinant and transgenic systems. Blood
Cells Mol Dis 28: 234–248.
13. Becker S, Simpson JC, Pepperkok R, Heinz S, Herder C, et al. (2004) Confocal
microscopy analysis of native, full length and B-domain deleted coagulation
factor VIII trafficking in mammalian cells. Thromb Haemost 92: 23–35.
14. Ellgaard L, Molinari M, Helenius A (1999) Setting the standards: quality control
in the secretory pathway. Science 286: 1882–1888.
15. Swaroop M, Moussalli M, Pipe SW, Kaufman RJ (1997) Mutagenesis of a
potential immunoglobulin-binding protein-binding site enhances secretion of
coagulation factor VIII. J Biol Chem 272: 24121–24124.
16. Pipe SW, Morris JA, Shah J, Kaufman RJ (1998) Differential interaction of
coagulation factor VIII and factor V with protein chaperones calnexin and
calreticulin. J Biol Chem 273: 8537–8544.
17. Plantier JL, Guillet B, Ducasse C, Enjolras N, Rodriguez MH, et al. (2005) B-
domain deleted factor VIII is aggregated and degraded through proteasomal
and lysosomal pathways. Thromb Haemost 93: 824–832.
18. Pittman DD, Alderman EM, Tomkinson KN, Wang JH, Giles AR, et al. (1993)
Biochemical, immunological, and in vivo functional characterization of B-
domain-deleted factor VIII. Blood 81: 2925–2935.
19. Miao HZ, Sirachainan N, Palmer L, Kucab P, Cunningham MA, et al. (2004)
Bioengineering of coagulation factor VIII for improved secretion. Blood 103:
3412–3419.
20. Connelly S, Andrews JL, Gallo AM, Kayda DB, Qian J, et al. (1998) Sustained
phenotypic correction of murine hemophilia A by in vivo gene therapy. Blood
91: 3273–3281.
21. Dooriss KL, Denning G, Gangadharan B, Javazon EH, McCarty DA, et al.
(2009) Comparison of factor VIII transgenes bioengineered for improved
expression in gene therapy of hemophilia A. Hum Gene Ther 20: 465–478.
22. Graw J, Brackmann HH, Oldenburg J, Schneppenheim R, Spannagl M, et al.
(2005) Haemophilia A: from mutation analysis to new therapies. Nat Rev Genet
6: 488–501.
23. Collins P, Faradji A, Morfini M, Enriquez MM, Schwartz L (2010) Efficacy and
safety of secondary prophylactic vs. on-demand sucrose-formulated recombinant
factor VIII treatment in adults with severe hemophilia A: results from a 13-
month crossover study. J. Thromb Haemost 8: 83–89.
24. Bi L, Lawler AM, Antonarakis SE, High KA, Gearhart JD, et al. (1995)
Targeted disruption of the mouse factor VIII gene produces a model of
haemophilia A. Nat Genet 10: 119–121.
25. Schuettrumpf J, Herzog RW, Schlachterman A, Kaufhold A, Stafford DW, et al.
(2005) Factor IX variants improve gene therapy efficacy for hemophilia B. Blood
105: 2316–2323.
26. Schuttrumpf J, Milanov P, Abriss D, Roth S, Tonn T, et al. (2011) Transgene
loss and changes in the promoter methylation status as determinants for
expression duration in nonviral gene transfer for factor IX. Hum Gene Ther 22:
101–106.
27. Tonn T, Herder C, Becker S, Seifried E, Grez M (2002) Generation and
characterization of human hematopoietic cell lines expressing factor VIII.
J Hematother Stem Cell Res 11: 695–704.
28. Heinz S, Schuttrumpf J, Simpson JC, Pepperkok R, Nicolaes GA, et al. (2009)
Factor VIII-eGFP fusion proteins with preserved functional activity for the
analysis of the early secretory pathway of factor VIII. Thromb Haemost 102:
925–935.
29. Mitta B, Rimann M, Ehrengruber MU, Ehrbar M, Djonov V, et al. (2002)
Advanced modular self-inactivating lentiviral expression vectors for multigene
interventions in mammalian cells and in vivo transduction. Nucleic Acids Res
30: 113.
30. Chen ZY, He CY, Kay MA (2005) Improved production and purification of
minicircle DNA vector free of plasmid bacterial sequences and capable of
persistent transgene expression in vivo. Hum Gene Ther 16: 126–131.
31. Mulugeta S, Maguire JA, Newitt JL, Russo SJ, Kotorashvili A, et al. (2007)
Misfolded BRICHOS SP-C mutant proteins induce apoptosis via caspase-4- and
cytochrome c-related mechanisms. Am J Physiol Lung Cell Mol Physiol 293:
L720–L729.
32. Singh LR, Chen X, Kozich V, Kruger WD (2007) Chemical chaperone rescue
of mutant human cystathionine beta-synthase. Mol Genet Metab 91: 335–342.
33. Tanaka M, Machida Y, Niu S, Ikeda T, Jana NR, et al. (2004) Trehalose
alleviates polyglutamine-mediated pathology in a mouse model of Huntington
disease. Nat Med 10: 148–154.
34. Furusho K, Yoshizawa T, Shoji S (2005) Ectoine alters subcellular localization of
inclusions and reduces apoptotic cell death induced by the truncated Machado-
Joseph disease gene product with an expanded polyglutamine stretch. Neurobiol
Dis. 20: 170–178.
35. Norez C, Antigny F, Becq F, Vandebrouck C (2006) Maintaining low Ca2+ level
in the endoplasmic reticulum restores abnormal endogenous F508del-CFTR
trafficking in airway epithelial cells. Traffic 7: 562–573.
36. Malhotra JD, Miao H, Zhang K, Wolfson A, Pennathur S, et al. (2008)
Antioxidants reduce endoplasmic reticulum stress and improve protein secretion.
Proc Natl Acad Sci USA 105: 18525–18530.
37. Guillet B, Lambert T, d’Oiron R, Proulle V, Plantier JL, et al. (2006) Detection
of 95 novel mutations in coagulation factor VIII gene F8 responsible for
hemophilia A: results from a single institution. Hum Mutat 27: 676–685.
38. Schatz SM, Zimmermann K, Hasslacher M, Kerschbaumer R, Dockal M, et al.
(2004) Mutation of the surface-exposed amino acid Trp to Ala in the FVIII C2
domain results in defective secretion of the otherwise functional protein.
Br J Haematol 125: 629–637.
39. Ryu JS, Kim TK, Chung JY, Lee GM (2000) Osmoprotective effect of glycine
betaine on foreign protein production in hyperosmotic recombinant chinese
hamster ovary cell cultures differs among cell lines. Biotechnol Bioeng 70: 167–
175.
40. Zhang B, Kaufman RJ, Ginsburg D (2005) LMAN1 and MCFD2 form a cargo
receptor complex and interact with coagulation factor VIII in the early secretory
pathway. J Biol Chem 280: 25881–25886.
41. Arakawa T, Timasheff SN (1985) The stabilization of proteins by osmolytes.
Biophys J 47: 411–414.
42. Bolen DW, Baskakov IV (2001) The osmophobic effect: natural selection of a
thermodynamic force in protein folding. J Mol Biol 310: 955–963.
43. Jia LY, Gong B, Pang CP, Huang Y, Lam DS, et al. (2009) Correction of the
disease phenotype of myocilin-causing glaucoma by a natural osmolyte. Invest
Ophthalmol Vis Sci 50: 3743–3749.
44. Zhang B, McGee B, Yamaoka JS, Guglielmone H, Downes KA, et al. (2006)
Combined deficiency of factor V and factor VIII is due to mutations in either
LMAN1 or MCFD2. Blood 107: 1903–1907.
45. Ben-Tekaya H, Miura K, Pepperkok R, Hauri HP (2005) Live imaging of
bidirectional traffic from the ERGIC. J Cell Sci 118: 357–367.
46. Marra P, Salvatore L, Mironov A Jr, Di Campli A, Di Tullio G, et al. (2007) The
biogenesis of the Golgi ribbon: the roles of membrane input from the ER and of
GM130. Mol Biol Cell 18: 1595–1608.
47. Zeisel SH, Mar MH, Howe JC, Holden JM (2003) Concentrations of choline-
containing compounds and betaine in common foods. J Nutr 133: 1302–1307.
48. Schwab U, Torronen A, Meririnne E, Saarinen M, Alfthan G, et al. (2006)
Orally administered betaine has an acute and dose-dependent effect on serum
betaine and plasma homocysteine concentrations in healthy humans. J Nutr 136:
34–38.
49. Fakharzadeh SS, Kazazian HH Jr (2000) Correlation between factor VIII
genotype and inhibitor development in hemophilia A. Semin Thromb Hemost
26(2): 167–71 Review.
50. Enjolras N, Plantier JL, Rodriguez MH, Rea M, Attali O, et al. (2004) Two
novel mutations in EGF-like domains of human factor IX dramatically impair
intracellular processing and secretion. J Thromb Haemost 2: 1143–1154.
51. Wang JW, Valentijn KM, de Boer HC, Dirven RJ, van Zonneveld AJ, et al.
(2011) Intracellular storage and regulated secretion of von Willebrand factor in
quantitative von Willebrand disease. J Biol Chem 286: 24180–24188.
Chemical Chaperones for Hemophilia A Therapy
PLOS ONE | www.plosone.org 13 September 2012 | Volume 7 | Issue 9 | e44505